Abstract
Stalled progress in controlling Plasmodium falciparum malaria highlights the need for an effective and deployable vaccine. RTS,S/AS01, the most effective malaria vaccine candidate to date, demonstrated 56% efficacy over 12 months in African children. We therefore assessed a new candidate vaccine for safety and efficacy. In this double-blind, randomised, controlled, phase 2b trial, the low-dose circumsporozoite protein-based vaccine R21, with two different doses of adjuvant Matrix-M (MM), was given to children aged 5-17 months in Nanoro, Burkina Faso-a highly seasonal malaria transmission setting. Three vaccinations were administered at 4-week intervals before the malaria season, with a fourth dose 1 year later. All vaccines were administered intramuscularly into the thigh. Group 1 received 5 μg R21 plus 25 μg MM, group 2 received 5 μg R21 plus 50 μg MM, and group 3, the control group, received rabies vaccinations. Children were randomly assigned (1:1:1) to groups 1-3. An independent statistician generated a random allocation list, using block randomisation with variable block sizes, which was used to assign participants. Participants, their families, and the local study team were all masked to group allocation. Only the pharmac...Continue Reading
References
May 25, 2011·Expert Review of Vaccines·Jason A RegulesChristian F Ockenhouse
Aug 6, 2011·Malaria Journal·Johan VekemansUNKNOWN Clinical Trials Partnership Committee
Oct 20, 2011·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia
Nov 10, 2012·The New England Journal of Medicine·UNKNOWN RTS,S Clinical Trials PartnershipPreeti Vansadia
Feb 7, 2013·Vaccine·Sofia E MagnussonLinda Stertman
Aug 30, 2013·Expert Review of Vaccines·Karin Lövgren BengtssonLinda Stertman
Nov 19, 2013·Lancet·Vasee S MoorthyJean-Marie Okwo-Bele
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Geert Leroux-RoelsJoe Cohen
Apr 29, 2015·Lancet·UNKNOWN RTS,S Clinical Trials Partnership
Sep 8, 2015·The Lancet Infectious Diseases·Michael T WhiteAzra C Ghani
Apr 27, 2016·Lancet·Bradford D GessnerAdam Finn
Apr 28, 2016·MBio·Sabra L KleinPeter Aaby
Jun 30, 2016·The New England Journal of Medicine·Ally OlotuPhilip Bejon
Dec 13, 2016·Trends in Parasitology·Irene N NkumamaFaith H A Osier
Apr 20, 2017·Scientific Reports·Katharine A CollinsAdrian V S Hill
Apr 14, 2018·Malaria Journal·Hamtandi Magloire NatamaAnna Rosanas-Urgell
Oct 17, 2018·NPJ Vaccines·Tommy RamplingAdrian V S Hill
Apr 24, 2019·Human Vaccines & Immunotherapeutics·Yolanda Guerra MendozaLode Schuerman
Apr 30, 2019·Lancet·Paul Adepoju
Jul 14, 2019·The Lancet Infectious Diseases·Halidou TintoJohn Lusingu
Feb 27, 2020·Vaccines·Alyse D PortnoffGale Smith
Aug 22, 2020·PLoS Medicine·Matthew E CairnsAlassane Dicko
Sep 3, 2020·The New England Journal of Medicine·Cheryl KeechGregory M Glenn
Sep 5, 2020·Nature·Gayathri Vaidyanathan
Citations
May 9, 2021·Lancet·Vasee Moorthy, Fred Binka
Jun 12, 2021·Nature Metabolism·Malcolm J McConville, Christian R Engwerda
Jun 28, 2021·Vaccine·Sylvester DassahMichael Theisen
Jul 2, 2021·Nature·Nana K Minkah, Stefan H I Kappe
Jul 13, 2021·PloS One·Surendra Kumar KolliChris J Janse
Jul 4, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Thomas NyirendaMichael Makanga
Aug 29, 2021·Vaccines·Jeffrey SeowRaymond S Norton
Sep 2, 2021·BMJ : British Medical Journal·Owen Dyer
Oct 13, 2021·Nature Microbiology·Irene N Nkumama, Faith H A Osier
Oct 14, 2021·NPJ Vaccines·Susheel K SinghMichael Theisen
Nov 21, 2021·Nature Communications·Sung-Jae ChaMarcelo Jacobs-Lorena